Cost Management Insights: SG&A Expenses for Biogen Inc. and BeiGene, Ltd.

Biogen vs. BeiGene: A Decade of SG&A Expense Trends

__timestamp	BeiGene, Ltd.	Biogen Inc.
Wednesday, January 1, 2014	6930000	2232342000
Thursday, January 1, 2015	7311000	2113100000
Friday, January 1, 2016	20097000	1947900000
Sunday, January 1, 2017	62602000	1935500000
Monday, January 1, 2018	195385000	2106300000
Tuesday, January 1, 2019	388249000	2374700000
Wednesday, January 1, 2020	600176000	2504500000
Friday, January 1, 2021	990123000	2674300000
Saturday, January 1, 2022	1277852000	2403600000
Sunday, January 1, 2023	1504501000	2549700000
Monday, January 1, 2024		2403700000

Data in motion

Navigating SG&A Expenses: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, Biogen Inc. and BeiGene, Ltd. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A expenses have remained relatively stable, averaging around $2.3 billion annually, with a modest increase of approximately 14% over the period. In contrast, BeiGene's SG&A expenses have skyrocketed, growing by an astonishing 21,600%, from a mere $6.93 million in 2014 to $1.5 billion in 2023. This dramatic rise reflects BeiGene's aggressive expansion and investment in global operations. As these companies continue to evolve, understanding their cost management strategies offers valuable insights into their operational priorities and market positioning.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025